More than 422 million people worldwide suffered from diabetes in 2014, driven by
increasing obesity rates that contribute to the rise of type 2 diabetes. This form of diabetes
occurs when the body resists insulin or doesn’t produce enough of it.
Zurich: On Tuesday, Swiss pharmaceutical company Roche announced plans to market a new
device leveraging artificial intelligence to help diabetics sleep better by predicting nocturnal
hypoglycemia. Diabetes, a chronic metabolic condition marked by elevated blood sugar
levels, is often managed with insulin injections. Patients can experience nighttime
hypoglycemia, which disrupts sleep and sometimes necessitates medical intervention.
Roche’s latest continuous glucose monitor, a wearable sensor, measures blood sugar every
five minutes and pairs with an AI app. The integrated AI algorithms predict hypoglycemia
risk within 30 minutes, forecast glucose levels for the next two hours, and estimate nocturnal
hypoglycemia risk. This technology allows proactive intervention before glucose levels
become critical, aiming to reduce nighttime hypoglycemia concerns. Roche stated the
predictive AI algorithms meet high accuracy standards and comply with European health and
safety regulations.
While generative AI applications like ChatGPT have captured public attention, AI is
increasingly used in various fields, including medical support through language translation
and image recognition.
Menu
